PRESAGE BIOSCIENCES IS BREAKING GROUND IN TRANSLATIONAL ONCOLOGY RESEARCH. WE ARE UNIQUELY POISED TO REPORT, IN DETAIL, WHAT HAPPENS WHEN THE TUMOR MICROENVIRONMENT IS EXPOSED TO DRUGS.
![[Downloader.la]-620b7b55ade30](https://presagebio.com/wp-content/uploads/2022/02/Downloader.la-620b7b55ade30.jpg)
About Presage
Presage’s patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology, directly encompassing a patient’s own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.
Cancer Drug Development Needs More Predictive Platforms For Testing Candidate Agents
One important bottleneck in oncology drug development is the inability of preclinical models to accurately model the tumor microenvironment in human patients.
Preclinical CIVO Offerings Available
CIVO highlights immune effects in syngeneic models
Preclinical CIVO Offerings Available
CIVO highlights immune effects in syngeneic models
- Experienced preclinical team
- In-house vivarium & IACUC
- Full tumor model, histology and image analysis support
- Excellent for pilot studies prior to Clinical CIVO
- Amenable to ALL drug modalities
- Small molecule
- I-O biologics
- Complex biologics (antibody-drug conjugates
- Novel delivery nanoparticles (exp. Exosomes)
- Live cell therapies (exp. CAR-T)
- Any combination of the above without drug reformulation!
Fundamentally changing cancer
drug development
In a few simple steps, this patented process can simultaneously evaluate multiple drugs or
drug combinations using 100+ assays for tumor microenvironment responses.
CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY
Presage A Translational
Oncology Company
Nine issued US patents
“A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.”
Presage's Partners
A pioneering solution, turnkey operation
A pioneering solution, turnkey operation, revenue-generating partnerships2016 - 2021
